Jump to main content
Jump to site search

Issue 2, 2008
Previous Article Next Article

Antitumour metal compounds: more than theme and variations

Author affiliations

Abstract

Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment of colon cancer should, however, not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs. Strategies opening up new avenues are increasingly being sought using complexes of metals other than platinum such as ruthenium or gallium. Based on the chemical differences between these metals, the spectrum of molecular mechanisms of action and potential indications can be broadened substantially. Other approaches focus on complexes with tumour-targeting properties, thereby maximizing the impact on cancer cells and minimizing the problem of adverse side effects, and complexes with biologically active ligands.

Graphical abstract: Antitumour metal compounds: more than theme and variations

Back to tab navigation

Publication details

The article was received on 16 Aug 2007, accepted on 24 Sep 2007 and first published on 07 Nov 2007


Article type: Perspective
DOI: 10.1039/B712656P
Citation: Dalton Trans., 2008,0, 183-194
  •   Request permissions

    Antitumour metal compounds: more than theme and variations

    M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger and B. K. Keppler, Dalton Trans., 2008, 0, 183
    DOI: 10.1039/B712656P

Search articles by author

Spotlight

Advertisements